ClinicalTrials.gg
RecruitingNCT06757049KOREA MITRISUpdated Oct 30, 2026

Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population

An observational study in Mitral Valve Insufficiency, sponsored by Asan Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Asan Medical Center · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 30, 2026First site in South KoreaNo longer in Korea, Republic of+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Mitral Valve Insufficiency · Korea, Republic of.

Started
2024
with 1 other
Observational
5 of 11
2 open now
Registered
10th of 11
by date
Lead sponsor
4 of 11
Asan Medical Center

Among the 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of, this one is one of 2 that started in 2024, is one of 5 observational ones, and was the 10th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

3 of the 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the early and mid-term safety and performance of the MITRIS RESILIA mitral valve in Asian patients in a real-world setting

Read the detailed description

This study is a prospective, investigator-Investigator initiated, multicenter observational study that aims to competitively register 200 patients who have undergone mitral valve replacement surgery with the MITRIS RESILIA mitral valve at participating institutions to collect real clinical outcomes.

This study will collect data on clinical outcomes obtained during standard care for patients who undergo mitral valve replacement surgery using the MITRIS RESILIA mitral valve in South Korea.

The aim is to recruit 200 patients using the MITRIS RESILIA mitral valve (competitive recruitment, no more than 100 per institution) over a period of two years.

All patients registered in the registry will be followed for five years. Follow-up assessments will occur at 6 months, 1 year, 2 years, 3 years, and 5 years post-surgery. Including the 2-year registration period and 5 years of follow-up for result analysis, the total study duration is expected to be approximately 7.5 years. However, the overall duration may vary depending on the rate of participant registration.

03

Conditions studied

  • Mitral Valve Insufficiency

Keywords

  • Mitral Valve Replacement
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Asian(REPUBLIC OF KOREA)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 19 or older
  2. Requires mitral valve replacement due to mitral valve dysfunction
  3. The participant or their guardian can provide a written consent form approved by the IRB and agree to the research protocol and clinical follow-up schedule.

Exclusion criteria

Exclusion Criteria:

  1. of less than one year due to causes other than cardiovascular disease
  2. High-risk candidates for mitral valve replacement: Society of Thoracic Surgeons Predicted Risk of Mortality 10% or greater; EuroSCORE 10% or greater; estimated surgical mortality rate by the surgeon 10% or greater
  3. Chronic kidney disease: \<30 mL/min/1.73m²
  4. Undergoing surgery for infective endocarditis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
60 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Cardiovascular death

    death that results from a disease of the heart or blood vessels

    Time frame: 1 year post-surgery

  2. Valve-related intervention

    a procedure to repair or replace a diseased or faulty heart valve

    Time frame: 1 year post-surgery

  3. Structural valve deterioration and non-structural valve dysfunction

    abnormality that's not intrinsic to the valve

    Time frame: 1 year post-surgery

Secondary outcomes

  1. Peak and mean trans-mitral valve pressure gradient and effective orifice area

    echocardiographic parameters used to assess mitral valve disease

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  2. All-cause death

    the total number of deaths from any cause in a given population over a specific period of time

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  3. cardiovascular death

    a death that results from a disease of the heart or blood vessels

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  4. Valve-related death

    any death that is caused by Structural valve deterioration,Nonstructural dysfunction,Valve thrombosis,Embolism,Bleeding event,Operated valve endocarditis,Death related to reintervention on the operated valve

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  5. Stroke (ischemic or hemorrhagic)

    a medical emergency that occurs when blood flow to the brain is blocked or a blood vessel in the brain bursts

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  6. Hospitalization due to cardiovascular disease

    a hospital admission with a defined cardiovascular cause

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  7. Bleeding

    BARC classification use.(A standardized tool for defining and categorizing bleeding events in clinical trials.)

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  8. Infective endocarditis related to the mitral valve

    a bacterial, viral, or fungal infection of the mitral valve leaflets

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  9. Valve-related reintervention

    any invasive procedure performed on the aortic valve, coronary button, or proximal aorta

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  10. Structural valve deterioration or non-structural valve dysfunction

    a type of valve dysfunction that involves permanent damage to the valve

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

  11. Valve thrombosis

    a rare but life-threatening condition that occurs when a thrombus forms on a prosthetic heart valve and interferes with blood flow or valve function

    Time frame: 6 month,1 year,2 year,3 year, 5year post-surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Mar 2031, 75 months after the start.

Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 75 months is above that.

Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2024
First posted
Jan 3, 2025
StartActual
Dec 20, 2024
Primary completionEst.
Mar 31, 2031
CompletionEst.
Mar 31, 2031
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed — first site in South Korea; no longer in Korea, Republic of
Show site
  • Asan Medical Center · Seoul, South Korea
Show 1 removed
  • Asan Medical Center · Seoul, Korea, Republic of
Oct 30, 2026
Contact
Study contact's phone or email changed: •••3815→•••3814. See the current contact
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    1 site added, 1 site removed — first site in South Korea; no longer in Korea, Republic of
    Show site
    • Asan Medical Center · Seoul, South Korea
    Show 1 removed
    • Asan Medical Center · Seoul, Korea, Republic of
    Contact Study contact's phone or email changed: •••3815→•••3814. See the current contact
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06757049
Responsible party
HO JIN KIM (Associate Professor, Asan Medical Center) — Principal investigator
First posted
Jan 3, 2025
Start date
Dec 20, 2024
Primary completion
Mar 31, 2031 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Oct 30, 2026

Study contacts

HOJIN KIM, PI
Contact
rhonin.hojin@gmail.com
82-2-3010-0506
YUKYUNG CHOI, CRA
Contact
cyk1108@amc.seoul.kr
82-2-2045-3814
HOJIN KIM, PI
study chair · cadiovascularthoracic surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion